AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
Keep up to date on AgNovos events and related news
On March 26th, Dr. James Howe, will present key data from the COPLEY proof-of-concept clinical study of OSSURE LOEP.
At ORS in San Diego, USA, Dr. Jonathan Shaul (PhD), Sr AgNovos Research Engineer will present pre-clinical data relating to the impact of OSSURE LOEP on the immediate biomechanical impact on cadaveric femurs.
Today, the CONFIRM clinical study began enrolling patients.
AgNovos is pleased to announce that Mr. Paul Laquerre has joined the Company as Executive Vice President and Chief Financial Officer.
AgNovos is proud to support the European Calcified Tissue Society (ECTS) in the formation of the ECTS Academy for top post-doctoral researchers in the European musculoskeletal field.
AgNovos is pleased to announce that Ron Hill, PhD has joined the Company as Vice President of R&D.